Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland. The company's lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system to support its pipel… Read more
Implantica AG (IMP-A-SDB) - Net Assets
Latest net assets as of September 2025: Skr89.53 Million SEK
Based on the latest financial reports, Implantica AG (IMP-A-SDB) has net assets worth Skr89.53 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr92.28 Million) and total liabilities (Skr2.75 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr89.53 Million |
| % of Total Assets | 97.02% |
| Annual Growth Rate | 38.08% |
| 5-Year Change | -12.82% |
| 10-Year Change | N/A |
| Growth Volatility | 313.79 |
Implantica AG - Net Assets Trend (2017–2024)
This chart illustrates how Implantica AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Implantica AG (2017–2024)
The table below shows the annual net assets of Implantica AG from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr100.16 Million | -19.90% |
| 2023-12-31 | Skr125.05 Million | -13.21% |
| 2022-12-31 | Skr144.09 Million | -9.90% |
| 2021-12-31 | Skr159.92 Million | +39.20% |
| 2020-12-31 | Skr114.89 Million | +896.50% |
| 2019-12-31 | Skr11.53 Million | -25.31% |
| 2018-12-31 | Skr15.44 Million | +47.52% |
| 2017-12-31 | Skr10.46 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Implantica AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13955419200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr129.35 Million | 125.91% |
| Other Comprehensive Income | Skr384.73 Million | 374.48% |
| Total Equity | Skr102.74 Million | 100.00% |
Implantica AG Competitors by Market Cap
The table below lists competitors of Implantica AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Skillz Platform Inc
NYSE:SKLZ
|
$29.87 Million |
|
Micropolis Holding Company
NYSE MKT:MCRP
|
$29.88 Million |
|
TVS Electronics Limited
NSE:TVSELECT
|
$29.88 Million |
|
China Tianrui Group Cement Company Limited
F:T18
|
$29.89 Million |
|
Ganesh Benzoplast Limited
NSE:GANESHBE
|
$29.87 Million |
|
Eureka Acquisition Corp Class A Ordinary Share
NASDAQ:EURK
|
$29.87 Million |
|
ROCHE BOBOIS S.A. EO5
F:5RO
|
$29.87 Million |
|
ELK-Desa Resources Bhd
KLSE:5228
|
$29.84 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Implantica AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 127,271,000 to 102,736,000, a change of -24,535,000 (-19.3%).
- Net loss of 23,333,000 reduced equity.
- Other comprehensive income decreased equity by 1,469,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-23.33 Million | -22.71% |
| Other Comprehensive Income | Skr-1.47 Million | -1.43% |
| Other Changes | Skr267.00K | +0.26% |
| Total Change | Skr- | -19.28% |
Book Value vs Market Value Analysis
This analysis compares Implantica AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 110.92x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 175.43x to 110.92x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | Skr0.23 | Skr40.25 | x |
| 2018-12-31 | Skr0.34 | Skr40.25 | x |
| 2019-12-31 | Skr0.26 | Skr40.25 | x |
| 2020-12-31 | Skr0.44 | Skr40.25 | x |
| 2021-12-31 | Skr0.57 | Skr40.25 | x |
| 2022-12-31 | Skr0.51 | Skr40.25 | x |
| 2023-12-31 | Skr0.45 | Skr40.25 | x |
| 2024-12-31 | Skr0.36 | Skr40.25 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Implantica AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.71%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1205.22%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 1.01x
- Recent ROE (-22.71%) is below the historical average (-22.04%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -30.27% | 0.00% | 0.00x | 1.29x | Skr-4.16 Million |
| 2018 | -30.17% | -25489.01% | 0.00x | 1.22x | Skr-6.06 Million |
| 2019 | -41.68% | -17160.71% | 0.00x | 1.71x | Skr-5.96 Million |
| 2020 | -8.95% | -6761.18% | 0.00x | 1.02x | Skr-21.77 Million |
| 2021 | -9.56% | -3969.25% | 0.00x | 1.02x | Skr-31.42 Million |
| 2022 | -14.31% | -2473.16% | 0.01x | 1.02x | Skr-35.38 Million |
| 2023 | -18.66% | -1686.36% | 0.01x | 1.02x | Skr-36.47 Million |
| 2024 | -22.71% | -1205.22% | 0.02x | 1.01x | Skr-33.61 Million |
Industry Comparison
This section compares Implantica AG's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $164,352,192
- Average return on equity (ROE) among peers: -116.65%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Implantica AG (IMP-A-SDB) | Skr89.53 Million | -30.27% | 0.03x | $29.87 Million |
| Acarix A/S (ACARIX) | $15.12 Million | -127.02% | 0.21x | $28.01 Million |
| Arcoma AB (ARCOMA) | $40.83 Million | -24.05% | 0.67x | $8.53 Million |
| Bactiguard Holding AB (publ) (BACTI-B) | $328.34 Million | -9.08% | 1.00x | $19.50 Million |
| CellaVision AB (CEVI) | $815.73 Million | 17.25% | 0.24x | $265.75 Million |
| Clinical Laserthermia Systems AB (publ) (CLS-B) | $21.18 Million | -300.30% | 2.15x | $13.01 Million |
| Chordate Medical Holding AB (CMH) | $10.98 Million | -226.67% | 0.72x | $17.64K |
| Coala Life Group AB (COALA) | $52.33 Million | -287.99% | 0.53x | $468.93K |
| C-Rad AB (publ) (CRAD-B) | $347.20 Million | 3.02% | 0.44x | $56.12 Million |
| Duearity AB (DEAR) | $11.04 Million | -140.58% | 0.46x | $34.43K |
| Episurf Medical AB (publ) (EPIS-B) | $759.76K | -71.11% | 0.59x | $5.40 Million |